Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.

BMC systems biology - 17 Jun 2015

Chamard-Jovenin Clémence, Jung Alain C, Chesnel Amand, Abecassis Joseph, Flament Stéphane, Ledrappier Sonia, Macabre Christine, Boukhobza Taha, Dumond Hélène

Abstract excerpt

BACKGROUND: Estrogen receptor alpha36 (ERalpha36), a variant of estrogen receptor alpha (ER) is expressed in about half of breast tumors, independently of the [ER+]/[ER-] status. In vitro, ERalpha36 triggers mitogenic non-genomic signaling and migration ability in response to 17beta-estradiol and tamoxifen. In vivo, highly ERalpha36 expressing tumors are of poor outcome especially as [ER+] tumors are submitted to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Computational Biology

Share to Disease Progression

Share to Estrogen Receptor alpha

Share to Gene Expression Regulation, Neoplastic

Share to Gene Regulatory Networks

Share to Neoplasm Metastasis

Source

Open in PubMed Open full text

Identifiers

PMID: 26080803
DOI: 10.1186/s12918-015-0178-7
PMCID: PMC4469423

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.PMID 26080803Read ↗

A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signalingSemantic proximity Read ↗

Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancerSemantic proximity Read ↗

The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancerSemantic proximity Read ↗

Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.Semantic proximity Read ↗

Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.Semantic proximity Read ↗

Estrogen Receptor Variant ER-α36 Facilitates Estrogen Signaling Via EGFR Signaling in GlioblastomaSemantic proximity Read ↗

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.Semantic proximity Read ↗

Gene expression signature of estrogen receptor alpha status in breast cancer.Semantic proximity Read ↗

MicroRNA-196a is regulated by ER and is a prognostic biomarker in ER+ Breast CancerSemantic proximity Read ↗

A phosphotyrosine switch determines the antitumor activity of ERβSemantic proximity Read ↗

Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.